Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric disorder treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Dr. Spyros Papapetropoulos, will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET, accessible through both the conference platform and Neuphoria's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NEUP declined 7.21%, reflecting a notable negative market reaction. Argus tracked a peak move of +25.3% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $30M at that time. Trading volume was very high at 3.6x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
The presentation will be available on demand here starting on Friday, September 5 at 7:00 a.m. ET. The webcast will also be available on the “Events” page in the investors section of Neuphoria’s website.
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC-210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC-210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Spyridon (Spyros) Papapetropoulos info@neuphoriatx.com | IR & PR Argot Partners neuphoria@argotpartners.com |
FAQ
When is Neuphoria Therapeutics (NEUP) presenting at the H.C. Wainwright Conference?
Who will be presenting for Neuphoria Therapeutics at the H.C. Wainwright Conference?
How can investors access Neuphoria Therapeutics' (NEUP) H.C. Wainwright presentation?
What type of company is Neuphoria Therapeutics (NEUP)?
